ENDPOINTS NEWS10h
End of obe­si­ty drug short­age threat­ens pa­tient ac­cess to com­pound­ed shots that Lil­ly calls risky
Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli ...
ENDPOINTS NEWS11h
WuXi com­pa­nies may sell units im­pact­ed by Biose­cure — re­port
WuXi AppTec and WuXi Biologics are reportedly looking to sell part of their operations that have struggled because of ...
ENDPOINTS NEWS11h
FDA's drug cen­ter launch­es new co­or­di­nat­ing body for mod­el­ing and sim­u­la­tion
The FDA's Center for Drug Evaluation and Research on Wednesday officially launched a new center of excellence to better ...
ENDPOINTS NEWS14h
Eli Lil­ly re­solves short­age for tirzepatide, po­ten­tial­ly end­ing com­pounder­s' run
Eli Lilly’s blockbuster GLP-1 drug tirzepatide is finally back on track in the US after two years of intermittent shortages ...
ENDPOINTS NEWS11h
Ex­clu­sive: Re­lay Ther­a­peu­tics cuts an­oth­er 10% of com­pa­ny, cit­ing con­tin­ued stream­lin­ing ef­forts
Relay Therapeutics is laying off 10% of its staff, or about 30 employees, in an additional round of job cuts after a smaller ...
ENDPOINTS NEWS10h
UK gov­ern­ment pro­pos­es phased roll­out of Eli Lil­ly's weight loss drug
The UK’s publicly funded healthcare system has proposed phasing its rollout of Eli Lilly’s weight loss treatment tirzepatide ...
ENDPOINTS NEWS13h
No­vo and Lil­ly out­line plans to mit­i­gate dis­rup­tions from US port strikes
Novo Nordisk and Eli Lilly, whose obesity drugs are some of the most in-demand drugs in the US, have drafted plans to avoid ...
ENDPOINTS NEWS23h
In­vestor Kur­ma Part­ners rais­es €140M for lat­est Eu­rope-fo­cused biotech fund
Kurma Partners has closed the first part of its latest biotech-focused fund, following a pair of M&A exits for drug ...
ENDPOINTS NEWS14h
Op­di­vo gets FDA ap­proval for use around lung can­cer surgery fol­low­ing Keytru­da and Imfinzi
The FDA greenlighted Bristol Myers Squibb’s Opdivo for use before and after surgery for non-small cell lung cancer. A regimen ...
ENDPOINTS NEWS14h
Flag­ship part­ners with key Sin­ga­pore R&D agency as it boosts APAC in­vest­ment
Flagship Pioneering's roots in Singapore are growing less than a year after the biotech incubator first unveiled its ...
ENDPOINTS NEWS22h
Enara Bio’s $32.5M Se­ries B to sup­port lead dark anti­gen pro­gram for GI can­cers
Enara Bio has snagged $32.5 million in a Series B fundraise, backed in part by Pfizer’s venture arm, to help develop a ...
ENDPOINTS NEWS15h
FDA lifts par­tial hold on Avid­i­ty’s my­oton­ic dy­s­tro­phy drug; Orum's IPO in South Ko­rea
Plus, news about Caliway Pharmaceuticals, argenx, Halozyme Therapeutics, Verrica, Liquidia and Pharmosa: FDA lifts partial clinical hold on Avidity Biosciences' drug: The treatment, called delpacibart ...